T-1095 is a selective and orally activeNa⁺-glucose cotransporter (SGLT)inhibitor withIC₅₀s of 22.8 μM and 2.3 μM for humanSGLT1andSGLT2, respectively. T-1095 can be used for diabetes research^[1].

T-1095 is absorbed into the circulation via oral administration, is metabolized to the active form, T-1095A, and suppresses the activity of SGLTs in the kidney^[1].
Orally administered T-1095 (3-30 mg/kg) increases urinary glucose excretion in diabetic animals, thereby decreasing blood glucose levels^[1].
With long-term T-1095 (0.01% or 0.1% T-1095 mixed diet; for 28 days) treatment, both blood glucose and HbA1c levels were reduced in streptozotocin (STZ)-induced diabetic rats and yellow KK mice. In addition, there was amelioration of abnormal carbohydrate metabolism, i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellow KK mice^[1].

516.49

C₂₆H₂₈O₁₁

209746-59-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.